Market News Video
MNV MNV 10 Stocks Crossing Above Their 200 Day Moving Average
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Commit To Buy La Jolla Pharmaceutical At $12.50, Earn 58.7% Annualized Using Options
Tuesday, July 5, 11:50 AM ET, by Market News Video Staff

Investors eyeing a purchase of La Jolla Pharmaceutical Co. (LJPC) shares, but tentative about paying ...

Noteworthy Monday Option Activity: SBUX, AA, LJPC
Monday, July 11, 11:28 AM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

Adding Up The Components: Russell 2000 Could Rise 10%
Thursday, August 11, 7:50 AM ET, by Market News Video Staff

The financial media loves to get predictions from experts about where they think a given ...

LJPC: Insiders vs. Shorts
Monday, August 22, 2:18 PM ET, by Market News Video Staff

The most recent short interest data was recently released for the 07/29/2016 settlement date, and ...

Commit To Buy La Jolla Pharmaceutical Co. At $15, Earn 24.5% Annualized Using Options
Tuesday, October 4, 11:35 AM ET, by Market News Video Staff

Investors eyeing a purchase of La Jolla Pharmaceutical Co. (LJPC) shares, but cautious about paying ...

  More articles:  1 2 3 4 5 6 7 next »

Insider Bets Paying Off At LJPC As New 52-Week High Reached

By Market News Video Staff, Monday, March 20, 1:05 PM ET
Play Video: The Importance of ETFs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Monday, shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) touched a new 52-week high of $39.28/share. That's a 175.84% rise, or $25.04 per share from the 52-week low of $14.24 set back on 05/06/2016. That means at today's intraday high, any investor who purchased LJPC stock any time over the past 52 weeks has an unrealized gain, including company insiders.

Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, LJPC has seen 5 different instances of insiders buying over the trailing six month period.

Purchased Insider Title Shares Price/Share Value
03/03/2017 George F. Tidmarsh President, CEO & Secretary 3,000 $34.17 $102,504.60
03/02/2017 Jennifer Carver Chief Operating Officer 1,000 $34.46 $34,459.75
03/03/2017 Lakhmir S. Chawla Chief Medical Officer 1,600 $34.80 $55,677.84
03/03/2017 Dennis Mulroy Chief Financial Officer 500 $33.95 $16,975.00
03/02/2017 Kevin C. Tang Director 100,000 $34.64 $3,463,840.00

The chart below shows where LJPC has traded over the past year, with the 50-day and 200-day moving averages included.

La Jolla Pharmaceutical Co. Moving Averages Chart

In afternoon trading on Monday, LJPC shares are changing hands at $38.70/share, slightly below the new 52-week high.

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Bargains   Cheaper   Chief   Director   Financial   George   Insider   Kevin   LJPC   Lakhmir   Medical   Monday   Mulroy   Officer   Over   Pharmaceutical   Price   Purchased   Share   Start   Tang   That   Value   afternoon   below   buying   changing   from   handsomely   have   high   insiders   intraday   month   months   over   past   period   purchased   rise   share   shares   summarized   table   time   touched   trading   week   where   with
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Stock Message Boards Stock Market Definitions

Insider Bets Paying Off At LJPC As New 52-Week High Reached | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.